Drug Profile
Etanercept biosimilar - Shanghai Celgen
Latest Information Update: 17 Nov 2021
Price :
$50
*
At a glance
- Originator Shanghai Celgen Bio-Pharmaceutical
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Plaque psoriasis
Most Recent Events
- 04 Oct 2019 Discontinued - Phase-III for Plaque psoriasis in China (SC)
- 01 Jan 2015 Phase-III clinical trials in Plaque psoriasis in China (SC)